No Cover Image

Journal article 36 views 12 downloads

Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

Samantha Ip Orcid Logo, Teri-Louise North, Fatemeh Torabi Orcid Logo, Yangfan Li, Hoda Abbasizanjani Orcid Logo, Ashley Akbari Orcid Logo, Elsie Horne, Rachel Denholm Orcid Logo, Spencer Keene, Spiros Denaxas, Amitava Banerjee Orcid Logo, Kamlesh Khunti, Cathie Sudlow Orcid Logo, William N. Whiteley Orcid Logo, Jonathan A. C. Sterne Orcid Logo, Angela M. Wood Orcid Logo, Venexia Walker Orcid Logo, (the CVD-COVID-UK/COVID-IMPACT Consortium), (the Longitudinal Health and Wellbeing COVID-19 National Core Study)

Nature Communications, Volume: 15, Issue: 1

Swansea University Authors: Fatemeh Torabi Orcid Logo, Hoda Abbasizanjani Orcid Logo, Ashley Akbari Orcid Logo

  • 67312.VoR.pdf

    PDF | Version of Record

    This article is licensed under a Creative Commons Attribution 4.0 International License.

    Download (1.17MB)

Check full text

DOI (Published version): 10.1038/s41467-024-49634-x

Abstract

The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in...

Full description

Published in: Nature Communications
ISSN: 2041-1723
Published: Springer Science and Business Media LLC 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa67312
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2024-09-17T13:30:41Z
last_indexed 2024-09-17T13:30:41Z
id cronfa67312
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>67312</id><entry>2024-08-04</entry><title>Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England</title><swanseaauthors><author><sid>f569591e1bfb0e405b8091f99fec45d3</sid><ORCID>0000-0002-5853-4625</ORCID><firstname>Fatemeh</firstname><surname>Torabi</surname><name>Fatemeh Torabi</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>93dd7e747f3118a99566c68592a3ddcc</sid><ORCID>0000-0002-9575-4758</ORCID><firstname>Hoda</firstname><surname>Abbasizanjani</surname><name>Hoda Abbasizanjani</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>aa1b025ec0243f708bb5eb0a93d6fb52</sid><ORCID>0000-0003-0814-0801</ORCID><firstname>Ashley</firstname><surname>Akbari</surname><name>Ashley Akbari</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-08-04</date><deptcode>MEDS</deptcode><abstract>The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.</abstract><type>Journal Article</type><journal>Nature Communications</journal><volume>15</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2041-1723</issnElectronic><keywords/><publishedDay>31</publishedDay><publishedMonth>7</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-07-31</publishedDate><doi>10.1038/s41467-024-49634-x</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This work was supported by the Longitudinal Health and Wellbeing COVID-19 National Core Study (UKRI Medical Research Council MC_PC_20030 and MC_PC_20059); and by the CONVALESCENCE long COVID study, funded by the UK National Institute for Health and Care Research (COVID-LT-009). This study was also supported by core funding from the: British Heart Foundation (RG/18/13/33946), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*], Cambridge BHF Centre of Research Excellence (RE/18/1/34212), BHF Chair Award (CH/12/2/29428) and by Health Data Research UK, which receives its funding from HDR UK Ltd (HDR-9006), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. The British Heart Foundation (BHF) Data Science Centre, led by Health Data Research (HDR) UK (BHF Grant no. SP/19/3/34678, awarded to HDR UK) also supported this work. This study made use of de-identified data held in NHS England’s Secure Data Environment service for England and made available via the BHF Data Science Centre’s CVD-COVID-UK/COVID-IMPACT consortium. This work used data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make health relevant data available for research. The BHF Data Science Centre funded co-development (with NHS England) of the Secure Data Environment service for England, provision of linked datasets, data access, user software licenses, computational usage, and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser’s National Core Studies programme to coordinate national COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians. Further support came from the Con-COV team funded by the Medical Research Council (grant number: MR/V028367/1) and the ADR Wales programme, part of the ADR UK investment, which unites expertise from Swansea University Medical School, WISERD at Cardiff University, and Welsh Government analysts. ADR UK is funded by the Economic and Social Research Council (ESRC), part of UK Research and Innovation. This research was also supported by ESRC funding, including Administrative Data Research Wales (ES/W012227/1). S.I. was funded by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK C18081/A31373, Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London and the University of Manchester. S.I. and Y.L. are supported by Cancer Research UK EDDPMA-May22\100062. A.B. has received funding from NIHR (COV-LT2-0043) as PI of the STIMULATE-ICP study. V.W. is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00032/03]. R.D. and J.A.C.S. are supported by the NIHR Bristol Biomedical Research Centre (NIHR203315) and by Health Data Research UK South-West (HDRUK2023.0022). A.M.W. and JACS are supported by the National Institute for Health Research (NIHR) (NIHR135073). A.M.W. is supported by the BHF Data Science Centre (HDRUK2023.0239) and as an NIHR Research Professor (NIHR303137). A.M.W. conducted this research whilst part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074 and whilst supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). The views expressed are those of the author(s) and not necessarily those of NIHR or the Department of Health and Social Care.</funders><projectreference/><lastEdited>2024-09-17T14:40:38.4541828</lastEdited><Created>2024-08-04T19:26:58.8729941</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Health Data Science</level></path><authors><author><firstname>Samantha</firstname><surname>Ip</surname><orcid>0000-0001-9162-6727</orcid><order>1</order></author><author><firstname>Teri-Louise</firstname><surname>North</surname><order>2</order></author><author><firstname>Fatemeh</firstname><surname>Torabi</surname><orcid>0000-0002-5853-4625</orcid><order>3</order></author><author><firstname>Yangfan</firstname><surname>Li</surname><order>4</order></author><author><firstname>Hoda</firstname><surname>Abbasizanjani</surname><orcid>0000-0002-9575-4758</orcid><order>5</order></author><author><firstname>Ashley</firstname><surname>Akbari</surname><orcid>0000-0003-0814-0801</orcid><order>6</order></author><author><firstname>Elsie</firstname><surname>Horne</surname><order>7</order></author><author><firstname>Rachel</firstname><surname>Denholm</surname><orcid>0000-0002-8067-5440</orcid><order>8</order></author><author><firstname>Spencer</firstname><surname>Keene</surname><order>9</order></author><author><firstname>Spiros</firstname><surname>Denaxas</surname><order>10</order></author><author><firstname>Amitava</firstname><surname>Banerjee</surname><orcid>0000-0001-8741-3411</orcid><order>11</order></author><author><firstname>Kamlesh</firstname><surname>Khunti</surname><order>12</order></author><author><firstname>Cathie</firstname><surname>Sudlow</surname><orcid>0000-0002-7725-7520</orcid><order>13</order></author><author><firstname>William N.</firstname><surname>Whiteley</surname><orcid>0000-0002-4816-8991</orcid><order>14</order></author><author><firstname>Jonathan A. C.</firstname><surname>Sterne</surname><orcid>0000-0001-8496-6053</orcid><order>15</order></author><author><firstname>Angela M.</firstname><surname>Wood</surname><orcid>0000-0002-7937-304x</orcid><order>16</order></author><author><firstname>Venexia</firstname><surname>Walker</surname><orcid>0000-0001-5064-446x</orcid><order>17</order></author><author><firstname>(the CVD-COVID-UK/COVID-IMPACT</firstname><surname>Consortium)</surname><order>18</order></author><author><firstname>(the Longitudinal Health and Wellbeing COVID-19 National Core</firstname><surname>Study)</surname><order>19</order></author></authors><documents><document><filename>67312__31353__97d1bd47cf2341d9b2fde5ff7a50dad1.pdf</filename><originalFilename>67312.VoR.pdf</originalFilename><uploaded>2024-09-17T14:35:15.1009793</uploaded><type>Output</type><contentLength>1231228</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This article is licensed under a Creative Commons Attribution 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 67312 2024-08-04 Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England f569591e1bfb0e405b8091f99fec45d3 0000-0002-5853-4625 Fatemeh Torabi Fatemeh Torabi true false 93dd7e747f3118a99566c68592a3ddcc 0000-0002-9575-4758 Hoda Abbasizanjani Hoda Abbasizanjani true false aa1b025ec0243f708bb5eb0a93d6fb52 0000-0003-0814-0801 Ashley Akbari Ashley Akbari true false 2024-08-04 MEDS The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs. Journal Article Nature Communications 15 1 Springer Science and Business Media LLC 2041-1723 31 7 2024 2024-07-31 10.1038/s41467-024-49634-x COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University This work was supported by the Longitudinal Health and Wellbeing COVID-19 National Core Study (UKRI Medical Research Council MC_PC_20030 and MC_PC_20059); and by the CONVALESCENCE long COVID study, funded by the UK National Institute for Health and Care Research (COVID-LT-009). This study was also supported by core funding from the: British Heart Foundation (RG/18/13/33946), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*], Cambridge BHF Centre of Research Excellence (RE/18/1/34212), BHF Chair Award (CH/12/2/29428) and by Health Data Research UK, which receives its funding from HDR UK Ltd (HDR-9006), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. The British Heart Foundation (BHF) Data Science Centre, led by Health Data Research (HDR) UK (BHF Grant no. SP/19/3/34678, awarded to HDR UK) also supported this work. This study made use of de-identified data held in NHS England’s Secure Data Environment service for England and made available via the BHF Data Science Centre’s CVD-COVID-UK/COVID-IMPACT consortium. This work used data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make health relevant data available for research. The BHF Data Science Centre funded co-development (with NHS England) of the Secure Data Environment service for England, provision of linked datasets, data access, user software licenses, computational usage, and data management and wrangling support, with additional contributions from the HDR UK Data and Connectivity component of the UK Government Chief Scientific Adviser’s National Core Studies programme to coordinate national COVID-19 priority research. Consortium partner organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and clinicians. Further support came from the Con-COV team funded by the Medical Research Council (grant number: MR/V028367/1) and the ADR Wales programme, part of the ADR UK investment, which unites expertise from Swansea University Medical School, WISERD at Cardiff University, and Welsh Government analysts. ADR UK is funded by the Economic and Social Research Council (ESRC), part of UK Research and Innovation. This research was also supported by ESRC funding, including Administrative Data Research Wales (ES/W012227/1). S.I. was funded by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK C18081/A31373, Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London and the University of Manchester. S.I. and Y.L. are supported by Cancer Research UK EDDPMA-May22\100062. A.B. has received funding from NIHR (COV-LT2-0043) as PI of the STIMULATE-ICP study. V.W. is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00032/03]. R.D. and J.A.C.S. are supported by the NIHR Bristol Biomedical Research Centre (NIHR203315) and by Health Data Research UK South-West (HDRUK2023.0022). A.M.W. and JACS are supported by the National Institute for Health Research (NIHR) (NIHR135073). A.M.W. is supported by the BHF Data Science Centre (HDRUK2023.0239) and as an NIHR Research Professor (NIHR303137). A.M.W. conducted this research whilst part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074 and whilst supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). The views expressed are those of the author(s) and not necessarily those of NIHR or the Department of Health and Social Care. 2024-09-17T14:40:38.4541828 2024-08-04T19:26:58.8729941 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Health Data Science Samantha Ip 0000-0001-9162-6727 1 Teri-Louise North 2 Fatemeh Torabi 0000-0002-5853-4625 3 Yangfan Li 4 Hoda Abbasizanjani 0000-0002-9575-4758 5 Ashley Akbari 0000-0003-0814-0801 6 Elsie Horne 7 Rachel Denholm 0000-0002-8067-5440 8 Spencer Keene 9 Spiros Denaxas 10 Amitava Banerjee 0000-0001-8741-3411 11 Kamlesh Khunti 12 Cathie Sudlow 0000-0002-7725-7520 13 William N. Whiteley 0000-0002-4816-8991 14 Jonathan A. C. Sterne 0000-0001-8496-6053 15 Angela M. Wood 0000-0002-7937-304x 16 Venexia Walker 0000-0001-5064-446x 17 (the CVD-COVID-UK/COVID-IMPACT Consortium) 18 (the Longitudinal Health and Wellbeing COVID-19 National Core Study) 19 67312__31353__97d1bd47cf2341d9b2fde5ff7a50dad1.pdf 67312.VoR.pdf 2024-09-17T14:35:15.1009793 Output 1231228 application/pdf Version of Record true This article is licensed under a Creative Commons Attribution 4.0 International License. true eng http://creativecommons.org/licenses/by/4.0/
title Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
spellingShingle Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
Fatemeh Torabi
Hoda Abbasizanjani
Ashley Akbari
title_short Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
title_full Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
title_fullStr Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
title_full_unstemmed Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
title_sort Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
author_id_str_mv f569591e1bfb0e405b8091f99fec45d3
93dd7e747f3118a99566c68592a3ddcc
aa1b025ec0243f708bb5eb0a93d6fb52
author_id_fullname_str_mv f569591e1bfb0e405b8091f99fec45d3_***_Fatemeh Torabi
93dd7e747f3118a99566c68592a3ddcc_***_Hoda Abbasizanjani
aa1b025ec0243f708bb5eb0a93d6fb52_***_Ashley Akbari
author Fatemeh Torabi
Hoda Abbasizanjani
Ashley Akbari
author2 Samantha Ip
Teri-Louise North
Fatemeh Torabi
Yangfan Li
Hoda Abbasizanjani
Ashley Akbari
Elsie Horne
Rachel Denholm
Spencer Keene
Spiros Denaxas
Amitava Banerjee
Kamlesh Khunti
Cathie Sudlow
William N. Whiteley
Jonathan A. C. Sterne
Angela M. Wood
Venexia Walker
(the CVD-COVID-UK/COVID-IMPACT Consortium)
(the Longitudinal Health and Wellbeing COVID-19 National Core Study)
format Journal article
container_title Nature Communications
container_volume 15
container_issue 1
publishDate 2024
institution Swansea University
issn 2041-1723
doi_str_mv 10.1038/s41467-024-49634-x
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Health Data Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Health Data Science
document_store_str 1
active_str 0
description The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.
published_date 2024-07-31T14:40:37Z
_version_ 1810450808600264704
score 11.028798

Similar Items